Ajanta Pharma Q3 Review - Branded Generics Continue To Grow; Margins Strong: ICICI Direct 
An employee holds Niacin tablets for a photograph inside a coating unit at the Lupin Ltd. pharmaceutical plant in Salcette, Goa, India. (Photographer: Dhiraj Singh/Bloomberg)

Ajanta Pharma Q3 Review - Branded Generics Continue To Grow; Margins Strong: ICICI Direct 


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Ajanta Pharma Ltd.’s Q3 FY21 revenues grew 15.0% YoY to Rs 749 crore. Domestic sales grew 12.8% to Rs 220 crore whereas emerging markets (branded) grew 19.2% YoY to Rs 286 crore.

U.S. sales remained muted (up 1.3% YoY) at Rs 161 crore. Africa tender business grew 57.1% YoY to Rs 77 crore.

Ebitda margins improved 372 basis points YoY to 32.3% amid better gross margins. Hence, Ebitda grew 30.0% YoY to Rs 242 crore.

Profit after tax grew 63.7% YoY to Rs 177 crore. Delta vis-a--vis Ebitda was mainly due to lower tax rate (18.0% versus 38.6% in Q3 FY20).

Click on the attachment to read the full report:

ICICI Direct Ajanta Pharma Q3FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.